we currently have three product candidates in clinical trials but we do not have any product candidates approved for sale , and we continue to incur significant research and development and general administrative expenses related to our operations . we are not profitable and have incurred losses in each year since our founding in 2008. our net loss was $ 43.1 million for the year ended december 31 , 2017. as of december 31 , 2017 , we had an accumulated deficit of $ 219.5 million . we expect to continue to incur significant losses for the foreseeable future . regulatory agencies , including the fda , regulate many aspects of a product candidate 's life cycle , including research and development and preclinical and clinical testing . we will need to commit significant time , resources , and funding to develop our two wholly owned product candidates in clinical trials , cx-072 and cx-2009 , as well as any additional product candidates for which we file inds in 2018 and beyond . we are unable to provide the nature , timing , and estimated costs of the efforts necessary to complete the development of our product candidates because , among other reasons , we can not predict with any certainty the pace of enrollment of our clinical trials , which is a function of many factors , including the availability and proximity of patients with the relevant condition . we currently have no manufacturing capabilities and do not intend to establish any such capabilities in the near term . as such , we are dependent on third parties to supply our product candidates according to our specifications , in sufficient quantities , on time , in compliance with appropriate regulatory standards and at competitive prices . 80 components of results of operations revenue our revenue to date has been primarily derived from non-refundable license payments , milestone payments and reimbursements for research and development expenses under our research , collaboration , and license agreements . we recognize revenue from upfront payments ratably over the term of our estimated period of performance under the agreement . in addition to receiving upfront payments , we may also be entitled to milestone and other contingent payments upon achieving predefined objectives . revenue from milestones , if they are nonrefundable and deemed substantive , is recognized upon successful accomplishment of the milestones . to the extent that non-substantive milestones are achieved and we have remaining performance obligations , milestones are deferred and recognized as revenue over the estimated remaining period of performance . reimbursements from pfizer and bms for research and development costs incurred under our research , collaboration and license agreements with them are classified as revenue . for the foreseeable future , we do not expect to generate any revenue from the sale of products unless and until such time as our product candidates have advanced through clinical development and obtained regulatory approval . we expect that any revenue we do generate in the foreseeable future will fluctuate from year to year as a result of the timing and amount of milestone and other payments from our collaborations with abbvie , amgen , bms , immunogen and pfizer , and any future collaboration partners , and as a result of the fluctuations in the research and development expenses we incur in the performance of assigned activities under these agreements . research and development expenses our research and development expenses consist primarily of costs incurred to conduct research , such as the discovery and development of our product candidates , clinical development including activities with third parties , such as clinical research organizations ( “ cros ” ) and contract manufacturing organizations ( “ cmos ” ) , drug products we used in clinical trials , as well as the development of product candidates pursuant to our research , collaboration and license agreements . research and development expenses include personnel costs , including stock-based compensation expense , contractor services , laboratory materials and supplies , depreciation and maintenance of research equipment , and an allocation of related facilities costs . we expense research and development costs as they are incurred . we expect our research and development expenses to increase substantially in absolute dollars in the future as we advance our product candidates through clinical trials , initiate additional clinical trials , and pursue regulatory approval of our product candidates . for example , we commenced enrollment of our phase 1/2 clinical trial of cx-072 , our candidate directed against pd-l1 , for cancer and treated our first patient in january 2017 , and our phase 1/2 clinical trial of cx-2009 , our pdc candidate directed against cd-166 , for cancer in june 2017. in addition , we currently expect to file inds for cx-2029 , our lead clinical candidate under our cd71 collaboration with abbvie inc. , in the first half of 2018 , and cx-188 , our wholly owned pd-1-targeting probody therapeutic , in the second half of 2018 ; however , the filing of such inds is subject to the satisfaction of certain conditions . the process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming . the actual probability of success for our product candidates may be affected by a variety of factors including : the safety and efficacy of our product candidates , early clinical data , investment in our clinical program , the ability of collaborators to successfully develop our licensed product candidates , competition , manufacturing capability and commercial viability . we may never succeed in achieving regulatory approval for any of our product candidates . as a result of the uncertainties discussed above , we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates . story_separator_special_tag the above table also excludes unrecognized tax benefits of $ 4.3 million as of december 31 , 2017 because these uncertain tax positions , if recognized , would be an adjustment to our deferred tax assets . segment information we have one primary business activity and operate as one reportable segment . critical accounting policies and estimates our management 's discussion and analysis of our financial condition and results of operations is based on our financial statements , which have been prepared in accordance with united states generally accepted accounting principles ( “ u.s . gaap ” ) . the preparation of these financial statements requires our management to make judgments and estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements , as well as the reported revenue generated and expenses incurred during the reporting periods . our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances , the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources . actual results may differ from these judgments and estimates under different assumptions or conditions and any such differences may be material . we believe that the accounting policies discussed below are critical to understanding our historical and future performance , as these policies relate to the more significant areas involving management 's judgments and estimates . revenue recognition we recognize revenue when all of the following criteria are met : persuasive evidence of an arrangement exists ; transfer of technology has been completed or services have been rendered ; the price to the customer is fixed or determinable ; and collectability is reasonably assured . our revenues are primarily derived through our license , research , development and commercialization agreements . the terms of these types of agreements may include ( i ) licenses for our technology or programs , ( ii ) research and development services , and ( iii ) services or obligations in connection with participation in research or steering committees . payments to us under these arrangements typically include one or more of the following : nonrefundable upfront and license fees , research funding , milestone and other contingent payments for the achievement of defined collaboration objectives and certain preclinical , clinical , regulatory and sales-based events , as well as royalties on sales of any commercialized products . in arrangements involving the delivery of more than one element , each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting . the determination is based on whether the deliverable has “ standalone value ” to the customer . if a deliverable does not qualify as a separate unit of accounting , it is combined with the other applicable undelivered item ( s ) within the arrangement and these combined deliverables are treated as a single unit of accounting . the arrangement 's consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy , which includes vendor-specific objective evidence ( “ vsoe ” ) of selling price , if available , or third-party evidence of selling price if vsoe is not available , or the best estimate of selling price , if neither vsoe nor third-party evidence is available . payments or reimbursements for our research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis . when upfront payments are received and if there is no discernible pattern of performance and or objectively measurable performance measures do not exist , we recognize revenue ratably over the associated period of performance . 89 our collaboration and license agreements may include contingent payments related to specified research , development and regulatory milestones and sales-based milestones . such payments are typically payable under the collaborations when the collaboration partner claims or selects a target , or initiates or advances a covered product candidate in preclinical or clinical development , upon submission for marketing approval of a covered product with regulatory authorities , upon receipt of actual marketing approvals of a covered product or for additional indications , or upon the first commercial sale of a covered product . sales-based milestones are typically payable when annual sales of a covered product reach specified levels . each contingent and milestone payment is evaluated to determine whether it is substantive and at risk to both parties . we recognize any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which the milestone is achieved . any payments that are contingent upon achievement of a non-substantive milestone are recognized as revenue prospectively , when such payments become due and collectible , over the remaining expected performance period under the arrangement , which is generally the remaining period over which the research and development services are expected to be provided . accrued research and development expenses we record accruals for estimated costs of research , preclinical and clinical studies and contract manufacturing activities , which are a significant component of research and development expenses . a substantial portion of our ongoing research and development activities is conducted by third-party service providers , including cros . our contracts with cros generally include pass-through costs , such as regulatory expenses , investigator fees , travel costs and other miscellaneous costs . the financial terms of these contracts are subject to negotiations , which vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided to us under such contracts . we accrue the costs incurred under agreements with these third parties based on actual

cash flows from operating activities during the year ended december 31 , 2017 , cash provided by operating activities was $ 170.4 million , which consisted of a net loss of $ 43.1 million , non-cash charges of $ 23.5 million , and an increase of $ 190.0 million in our net operating assets and liabilities . the non-cash charges primarily consisted of $ 1.6 million in depreciation and amortization , $ 11.3 million in stock-based compensation and a $ 10.7 million non-cash acquisition of in-process research and development asset charged to expense . the change in our net operating assets and liabilities of $ 190.0 million was primarily attributable to : an increase of $ 189.9 million in deferred revenue resulting from bms upfront payment of $ 200.0 million and $ 40.0 million received in connection with the collaboration we entered into with amgen in september 2017. these increases were partially offset by an increase in the recognition of revenue associated with upfront fees of $ 34.4 million under our various collaboration agreements , $ 6.6 million in recognized revenue from our delivery of a development and commercialization license to immunogen in connection with our collaboration agreement , and $ 5.9 million in recognized revenue from immunogen as a result of the immunogen amendment ; an increase in accrued and long-term liabilities of $ 9.2 million ; and an increase in other assets of $ 1.6 million ; partially offset by a decrease in accounts receivable of $ 8.0 million resulting primarily from the $ 10.0 million of milestone billing to bms for the ind filing of the ctla-4 directed probody therapeutic , offset by $ 2.0 payment received from bms relating to the 2016 milestone for the selection of ctla-4 ecn designation ; and a decrease of $ 2.4 million in accounts payable .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows from operating activities during the year ended december 31 , 2017 , cash provided by operating activities was $ 170.4 million , which consisted of a net loss of $ 43.1 million , non-cash charges of $ 23.5 million , and an increase of $ 190.0 million in our net operating assets and liabilities . the non-cash charges primarily consisted of $ 1.6 million in depreciation and amortization , $ 11.3 million in stock-based compensation and a $ 10.7 million non-cash acquisition of in-process research and development asset charged to expense . the change in our net operating assets and liabilities of $ 190.0 million was primarily attributable to : an increase of $ 189.9 million in deferred revenue resulting from bms upfront payment of $ 200.0 million and $ 40.0 million received in connection with the collaboration we entered into with amgen in september 2017. these increases were partially offset by an increase in the recognition of revenue associated with upfront fees of $ 34.4 million under our various collaboration agreements , $ 6.6 million in recognized revenue from our delivery of a development and commercialization license to immunogen in connection with our collaboration agreement , and $ 5.9 million in recognized revenue from immunogen as a result of the immunogen amendment ; an increase in accrued and long-term liabilities of $ 9.2 million ; and an increase in other assets of $ 1.6 million ; partially offset by a decrease in accounts receivable of $ 8.0 million resulting primarily from the $ 10.0 million of milestone billing to bms for the ind filing of the ctla-4 directed probody therapeutic , offset by $ 2.0 payment received from bms relating to the 2016 milestone for the selection of ctla-4 ecn designation ; and a decrease of $ 2.4 million in accounts payable .
```    
 Suspicious Activity Report : we currently have three product candidates in clinical trials but we do not have any product candidates approved for sale , and we continue to incur significant research and development and general administrative expenses related to our operations . we are not profitable and have incurred losses in each year since our founding in 2008. our net loss was $ 43.1 million for the year ended december 31 , 2017. as of december 31 , 2017 , we had an accumulated deficit of $ 219.5 million . we expect to continue to incur significant losses for the foreseeable future . regulatory agencies , including the fda , regulate many aspects of a product candidate 's life cycle , including research and development and preclinical and clinical testing . we will need to commit significant time , resources , and funding to develop our two wholly owned product candidates in clinical trials , cx-072 and cx-2009 , as well as any additional product candidates for which we file inds in 2018 and beyond . we are unable to provide the nature , timing , and estimated costs of the efforts necessary to complete the development of our product candidates because , among other reasons , we can not predict with any certainty the pace of enrollment of our clinical trials , which is a function of many factors , including the availability and proximity of patients with the relevant condition . we currently have no manufacturing capabilities and do not intend to establish any such capabilities in the near term . as such , we are dependent on third parties to supply our product candidates according to our specifications , in sufficient quantities , on time , in compliance with appropriate regulatory standards and at competitive prices . 80 components of results of operations revenue our revenue to date has been primarily derived from non-refundable license payments , milestone payments and reimbursements for research and development expenses under our research , collaboration , and license agreements . we recognize revenue from upfront payments ratably over the term of our estimated period of performance under the agreement . in addition to receiving upfront payments , we may also be entitled to milestone and other contingent payments upon achieving predefined objectives . revenue from milestones , if they are nonrefundable and deemed substantive , is recognized upon successful accomplishment of the milestones . to the extent that non-substantive milestones are achieved and we have remaining performance obligations , milestones are deferred and recognized as revenue over the estimated remaining period of performance . reimbursements from pfizer and bms for research and development costs incurred under our research , collaboration and license agreements with them are classified as revenue . for the foreseeable future , we do not expect to generate any revenue from the sale of products unless and until such time as our product candidates have advanced through clinical development and obtained regulatory approval . we expect that any revenue we do generate in the foreseeable future will fluctuate from year to year as a result of the timing and amount of milestone and other payments from our collaborations with abbvie , amgen , bms , immunogen and pfizer , and any future collaboration partners , and as a result of the fluctuations in the research and development expenses we incur in the performance of assigned activities under these agreements . research and development expenses our research and development expenses consist primarily of costs incurred to conduct research , such as the discovery and development of our product candidates , clinical development including activities with third parties , such as clinical research organizations ( “ cros ” ) and contract manufacturing organizations ( “ cmos ” ) , drug products we used in clinical trials , as well as the development of product candidates pursuant to our research , collaboration and license agreements . research and development expenses include personnel costs , including stock-based compensation expense , contractor services , laboratory materials and supplies , depreciation and maintenance of research equipment , and an allocation of related facilities costs . we expense research and development costs as they are incurred . we expect our research and development expenses to increase substantially in absolute dollars in the future as we advance our product candidates through clinical trials , initiate additional clinical trials , and pursue regulatory approval of our product candidates . for example , we commenced enrollment of our phase 1/2 clinical trial of cx-072 , our candidate directed against pd-l1 , for cancer and treated our first patient in january 2017 , and our phase 1/2 clinical trial of cx-2009 , our pdc candidate directed against cd-166 , for cancer in june 2017. in addition , we currently expect to file inds for cx-2029 , our lead clinical candidate under our cd71 collaboration with abbvie inc. , in the first half of 2018 , and cx-188 , our wholly owned pd-1-targeting probody therapeutic , in the second half of 2018 ; however , the filing of such inds is subject to the satisfaction of certain conditions . the process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming . the actual probability of success for our product candidates may be affected by a variety of factors including : the safety and efficacy of our product candidates , early clinical data , investment in our clinical program , the ability of collaborators to successfully develop our licensed product candidates , competition , manufacturing capability and commercial viability . we may never succeed in achieving regulatory approval for any of our product candidates . as a result of the uncertainties discussed above , we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates . story_separator_special_tag the above table also excludes unrecognized tax benefits of $ 4.3 million as of december 31 , 2017 because these uncertain tax positions , if recognized , would be an adjustment to our deferred tax assets . segment information we have one primary business activity and operate as one reportable segment . critical accounting policies and estimates our management 's discussion and analysis of our financial condition and results of operations is based on our financial statements , which have been prepared in accordance with united states generally accepted accounting principles ( “ u.s . gaap ” ) . the preparation of these financial statements requires our management to make judgments and estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements , as well as the reported revenue generated and expenses incurred during the reporting periods . our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances , the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources . actual results may differ from these judgments and estimates under different assumptions or conditions and any such differences may be material . we believe that the accounting policies discussed below are critical to understanding our historical and future performance , as these policies relate to the more significant areas involving management 's judgments and estimates . revenue recognition we recognize revenue when all of the following criteria are met : persuasive evidence of an arrangement exists ; transfer of technology has been completed or services have been rendered ; the price to the customer is fixed or determinable ; and collectability is reasonably assured . our revenues are primarily derived through our license , research , development and commercialization agreements . the terms of these types of agreements may include ( i ) licenses for our technology or programs , ( ii ) research and development services , and ( iii ) services or obligations in connection with participation in research or steering committees . payments to us under these arrangements typically include one or more of the following : nonrefundable upfront and license fees , research funding , milestone and other contingent payments for the achievement of defined collaboration objectives and certain preclinical , clinical , regulatory and sales-based events , as well as royalties on sales of any commercialized products . in arrangements involving the delivery of more than one element , each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting . the determination is based on whether the deliverable has “ standalone value ” to the customer . if a deliverable does not qualify as a separate unit of accounting , it is combined with the other applicable undelivered item ( s ) within the arrangement and these combined deliverables are treated as a single unit of accounting . the arrangement 's consideration that is fixed or determinable is allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy , which includes vendor-specific objective evidence ( “ vsoe ” ) of selling price , if available , or third-party evidence of selling price if vsoe is not available , or the best estimate of selling price , if neither vsoe nor third-party evidence is available . payments or reimbursements for our research and development efforts for the arrangements where such efforts are considered as deliverables are recognized as the services are performed and are presented on a gross basis . when upfront payments are received and if there is no discernible pattern of performance and or objectively measurable performance measures do not exist , we recognize revenue ratably over the associated period of performance . 89 our collaboration and license agreements may include contingent payments related to specified research , development and regulatory milestones and sales-based milestones . such payments are typically payable under the collaborations when the collaboration partner claims or selects a target , or initiates or advances a covered product candidate in preclinical or clinical development , upon submission for marketing approval of a covered product with regulatory authorities , upon receipt of actual marketing approvals of a covered product or for additional indications , or upon the first commercial sale of a covered product . sales-based milestones are typically payable when annual sales of a covered product reach specified levels . each contingent and milestone payment is evaluated to determine whether it is substantive and at risk to both parties . we recognize any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which the milestone is achieved . any payments that are contingent upon achievement of a non-substantive milestone are recognized as revenue prospectively , when such payments become due and collectible , over the remaining expected performance period under the arrangement , which is generally the remaining period over which the research and development services are expected to be provided . accrued research and development expenses we record accruals for estimated costs of research , preclinical and clinical studies and contract manufacturing activities , which are a significant component of research and development expenses . a substantial portion of our ongoing research and development activities is conducted by third-party service providers , including cros . our contracts with cros generally include pass-through costs , such as regulatory expenses , investigator fees , travel costs and other miscellaneous costs . the financial terms of these contracts are subject to negotiations , which vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided to us under such contracts . we accrue the costs incurred under agreements with these third parties based on actual

